SHANGHAI, April 16, 2023 /PRNewswire/ — Abbisko (Stock Code: 2256.HK) announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting. These include its self-developed CSF-1R inhibitor Pimicotinib (ABSK021), which has…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.